Cronos Group Inc vs Lufax Holding Ltd — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Lufax Holding Ltd trades at $0.96 (market cap $1.01B). The key difference: Cronos Group Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Lufax Holding Ltd for 13 Days on average.
| CRON | LU | |
|---|---|---|
Market Cap | $1.20B | $1.01B |
Volume | 450,387 | 4,754,976 |
Sector | Health | Financials |
52-Week High | $3.55 | $3.93 |
52-Week Low | $2.30 | $0.95 |
Typical Hold Time | 22 Days | 13 Days |
Enterprise Value | $401.73M | $59.02B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
LU trades at $0.98, down 2.83% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and declining revenue trends. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Analyst consensus remains predominantly bullish with 69% buy ratings, citing deep value potential despite ongoing operational challenges.
LU presents a high-risk, event-driven opportunity with significant valuation discounts (P/S 0.26, P/B 0.07) but faces substantial execution risks amid regulatory pressures and persistent losses. The stock's outlook hinges on successful restructuring and potential Hong Kong listing catalysts, though near-term headwinds from China's consumer lending sector remain challenging for profitability recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →